Treatment of HER2-positive metastatic breast cancer.

Abstract

to th e ed ito r : Swain and colleagues (Feb. 19 issue)1 report an important overall survival ben­ efit of 15.7 months for the addition of pertuzumab to trastuzumab and docetaxel as first-line treatment of metastatic breast cancer that is positive for human epidermal growth factor re­ ceptor 2 (HER2). The study included a large pro­ portion of patients who… (More)
DOI: 10.1056/NEJMc1503446

Topics

Cite this paper

@article{Swain2015TreatmentOH, title={Treatment of HER2-positive metastatic breast cancer.}, author={Sandra M Swain and Emma M. Clark and Jos{\'e} Baselga}, journal={The New England journal of medicine}, year={2015}, volume={372 20}, pages={1964-5} }